HALO Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.…
Industry Peers
BiotechnologyKey Statistics
About Halozyme Therapeutics (NASDAQ: HALO)
›
Halozyme Therapeutics (NASDAQ: HALO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 423 employees.
The shares were at 93.17 USD on 19 November 2026, up 40.3% over 52 weeks. Its 52-week range is 61.23 USD to 133.96 USD: the price is 30.5% below the high and 52.2% above the low.
At a market capitalisation of 10.92B USD, it trades at 23.9 times trailing earnings and 9.0 times forward earnings. The median trailing P/E of its 14 largest Biotechnology peers is 34.5, a discount of 31% for HALO.
Halozyme Therapeutics reports an operating margin of 56.7% and revenue up 39.2% year over year.
Its debt exceeds its cash by 2.20B USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 119.89 USD is 28.7% above the current price. The next earnings report is expected on 16 February 2027.